This site is intended for health professionals only
Wednesday 12 December 2018
Share |

Topic: paediatrics

November 29, 2018
First child cancer patients treated with new CAR-T therapy in UK

Children with cancer at Great Ormond Street Hospital in London are this week starting a new therapy treatment tailored to target patients’ specific cancer cells.
 
The CAR-T treatment involves collecting and using a patient’s own immune cells to fight the cancer over a number of weeks. 
 
Royal Manchester Children’s Hospital is also offering the immunotherapy treatment, and Newcastle upon Tyne Hospitals NHS Foundation Trust will join next month.
 

October 25, 2018
The European Commission has granted Kigabeq paediatric use marketing authorisation (PUMA) following the recommendation of the Committee for Medicinal Products for Human Use (CHMP).

The European Commission has granted Kigabeq paediatric use marketing authorisation (PUMA) following the recommendation of the Committee for Medicinal Products for Human Use (CHMP).
 
Kigabeq is meant for the treatment of infantile spasms, or West’s syndrome, which is an uncommon and severe form of epilepsy associated with a highly-resistant seizure type and a rapid psychomotor regression. It can also be used to treat partial epilepsy in infants and children from one month to seven years of age.
 

October 25, 2018
The European Commission has granted Kigabeq paediatric use marketing authorisation (PUMA) following the recommendation of the Committee for Medicinal Products for Human Use (CHMP).

The European Commission has granted Kigabeq paediatric use marketing authorisation (PUMA) following the recommendation of the Committee for Medicinal Products for Human Use (CHMP).
 
Kigabeq is meant for the treatment of infantile spasms, or West’s syndrome, which is an uncommon and severe form of epilepsy associated with a highly-resistant seizure type and a rapid psychomotor regression. It can also be used to treat partial epilepsy in infants and children from one month to seven years of age.
 

October 17, 2018
Pharmacists must implement new validation processes from today (17 October) to prioritise the limited stocks of EpiPen junior 150 microgram (mcg), the Department of Health and Social Care (DHSC) and NHS England have said.

Pharmacists must implement new validation processes from today (17 October) to prioritise the limited stocks of EpiPen junior 150 microgram (mcg), the Department of Health and Social Care (DHSC) and NHS England have said.

June 28, 2018
First cannabinoid prescription medicine to be approved in the US endorses Epidiolex to treat two rare forms of childhood-onset epilepsy

The first cannabinoid prescription in the US has been given the green light by the US Food and Drug Administration (FDA) [June 25 2018].
 
GW Pharmaceuticals’ Epidiolex has been approved to treat two rare forms of childhood onset epilepsy - Lennox-Gastaut Syndrome (LGS) or Dravet Syndrome.
 

April 11, 2018
<p>The Scottish Medicines Consortium (SMC) has accepted Shire&#39;s Revestive&reg; (teduglutide) for restricted use in children aged one and above with short bowel syndrome</p>

Global biotechnology company Shire has announced that the Scottish Medicines Consortium (SMC) has accepted its Revestive® (teduglutide) 5mg and 1.25mg for restricted use in the treatment of children aged one year and above with short bowel syndrome (SBS).

 

February 9, 2018
Individualised parenteral nutrition (IPN) has an important role in the management of more nutritionally complex and fluid restricted preterm infants. This article provides an overview of, and current perspectives on, preterm IPN
September 16, 2016
Novo Nordisk today announced that the CHMP has adopted a positive opinion to extend the use of NovoRapid® (insulin aspart) in the EU for children with diabetes from as young as one year old

February 24, 2016
To highlight Rare Disease Day 2016 on 29 February, Swedish Orphan Biovitrum Ltd. (Sobi) is proud to sponsor 'The Rare Project', a project initiated by the not for profit organisation Same But Different

To highlight Rare Disease Day 2016 on 29 February, Swedish Orphan Biovitrum Ltd. (Sobi) is proud to sponsor 'The Rare Project', a project initiated by the not for profit organisation Same But Different.

 

January 19, 2016
Swedish Orphan Biovitrum AB (publ) (Sobi) announced that the European Patent Office (EPO) has decided to grant a European patent for the Orfadin® (nitisinone) oral suspension formulation

Swedish Orphan Biovitrum AB (publ) (Sobi) announced that the European Patent Office (EPO) has decided to grant a European patent for the Orfadin® (nitisinone) oral suspension formulation, which was approved by the European Commission for the treatment of Hereditary Tyrosinaemia type-1 (HT-1) in 2015. HT-1 is a rare genetic disease that affects infants and children. It is progressive and may result in liver and kidney complications and can be fatal if untreated.

 

January 19, 2016
Swedish Orphan Biovitrum AB (publ) (Sobi) announced that the European Patent Office (EPO) has decided to grant a European patent for the Orfadin® (nitisinone) oral suspension formulation

Swedish Orphan Biovitrum AB (publ) (Sobi) announced that the European Patent Office (EPO) has decided to grant a European patent for the Orfadin® (nitisinone) oral suspension formulation, which was approved by the European Commission for the treatment of Hereditary Tyrosinaemia type-1 (HT-1) in 2015. HT-1 is a rare genetic disease that affects infants and children. It is progressive and may result in liver and kidney complications and can be fatal if untreated.

 

June 26, 2015
Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the expanded use of Levemir® (insulin detemir) in children with diabetes as young as one year old

There are an estimated 497,100 children living with type I diabetes globally and incidence is increasing in many countries. (1) Young children with type I diabetes can be difficult to treat as their needs are in constant flux during growth and development, (2) with children aged six and under at greatest risk of severe hypoglycaemia and acute diabetes complications. (3)
 

 

May 27, 2008
Premature baby dies after pharmaceutical department "pressed the wrong button"

teaser

May 6, 2008
Rise in the rate of antipsychotics prescribed to UK children

teaser

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine